- freely available
Mar. Drugs 2012, 10(4), 890-899; doi:10.3390/md10040890
Published: 10 April 2012
Abstract: It has been suggested that oxidative stress activates various intracellular signaling pathways leading to secretion of a variety of pro-inflammatory cytokines and chemokines. SHP-1 is a protein tyrosine phosphatase (PTP) which acts as a negative regulator of immune cytokine signaling. However, intracellular hydrogen peroxide (H2O2), generated endogenously upon stimulation and exogenously from environmental oxidants, has been known to be involved in the process of intracellular signaling through inhibiting various PTPs, including SHP-1. In this study, we investigated the potential role of astaxanthin, an antioxidant marine carotenoid, in re-establishing SHP-1 negative regulation on pro-inflammatory cytokines secretion in U-937 cell line stimulated with oxidative stimulus. ELISA measurement suggested that ASTA treatment (10 µM) reduced pro-inflammatory cytokines secretion (IL-1β, IL-6 and TNF-α) induced through H2O2, (100 µM). Furthermore, this property is elicited by restoration of basal SHP-1 protein expression level and reduced NF-κB (p65) nuclear expression, as showed by western blotting experiments.
It is known that excess of reactive oxygen species (ROS) is associated to inflammation, growth and vasoconstriction contributing to vascular injury in many cardiovascular diseases, such as hypertension, hyperlipidemia, and diabetes [1,2,3]. Inflammation, a self-defense reaction against various pathogenic stimuli, it may become a harmful self-damaging process, if it transforms to chronic inflammation . Carotenoids are phytochemicals considered beneficial in the prevention of a variety of major diseases [5,6]. The marine carotenoid astaxanthin (ASTA) is naturally found in a wide variety of living organisms, such as microalgae, fungi, and crustaceans . Astaxanthin (3,3-dihydroxy-beta,beta-carotene-4,4-dione) belongs to the xanthophyll subclass of carotenoids. Several studies have demonstrated that ASTA possesses powerful antioxidant properties, both in vitro and in vivo, especially as an inhibitor of LDL oxidation . Evidence has suggested that the action of carotenoids on immunity and diseases may be mediated, at least in part, by their ability to quench and/or blench ROS . In recent years, a number of studies on astaxanthin have demonstrated its in vitro and in vivo antioxidant effect, for example, the quenching effect on singlet oxygen, a strong scavenging effect on superoxide, hydrogen peroxide, and hydroxyl radicals and an inhibitory effect on lipid peroxidation. The specific molecular mechanisms of its actions are not yet established [10,11]. Protein tyrosine phosphorylation (PTPs) plays a variety of significant roles in cell signaling transduction, physiological functions, and pathological processes [12,13]. In the PTP family, a subgroup of cytoplasmic PTPs characterized by containing two Src homology 2 (SH2) N-terminal domains and a C-terminal protein-tyrosine phosphatase domain are referred to as SHP. They are intimately involved in several cellular activities, such as cytoskeletal maintenance, cell division, and cell differentiation [14,15]. Phosphorylation of proteins serves to alter their activity, providing a simple and mostly reversible change in molecular function. Interest in the diverse biology of protein tyrosine phosphatases that are encoded by more than 100 genes in the human genome continues to grow at an accelerated pace . In particular, two cytoplasmic protein tyrosine phosphatases composed of two Src homology 2 (SH2) N-terminal domains and a C-terminal protein-tyrosine phosphatase domain referred to as SHP-1 and SHP-2 are known to govern a host of cellular functions [17,18].
Most recently, SHP-1 deficiency was found to increase inflammatory gene expression and enhance activation of transcription factor STAT6, STAT1, and NF-κB in PBMC and macrophages of patients with multiple sclerosis [19,20]. Because oxidants are released early in inflammation and have been found to regulate transcription factors, the aim of the present study was to evaluate the in vitro effect of carotenoid astaxanthin (ASTA) in inflammation through the evaluation of cytokine release, SHP-1 expression and reactive oxygen species production on U937 cells stimulated with H2O2.
2. Results and Discussion
2.1. Cell Viability
It has been well established that oxidative agents, such as H2O2, can induce cell death . In order to investigate the influence of ASTA on immunitary cell viability, we treated U937 cells with H2O2, and examined its effects. Since a concentration of 100 µM H2O2 and an incubation time of 12 h were previously identified as optimal time and concentration (data not shown) for the induction of deleterious effects on U937 cell viability, these conditions were selected for the rest of experiments. The viability of cells exposed to 100 µM H2O2 for 12 h was 61.5 ± 2.8% vs. 96.0 ± 2.8% of the control value, while the viability of cells that were pre-treated for 24 h with ASTA at a concentration of 10 μM prior to 12 h exposure to H2O2 increased significantly to 78.1 ± 1.9% (p < 0.01) (Table 1). These results indicate that the viability of H2O2-treated cells decreased significantly, but that the ASTA exerted a protective effect against the H2O2-induced cytotoxicity.
|Table 1. Effect of astaxanthin (ASTA) upon cell viability evaluated by MTT assay. U937 cells were pre-treated with ASTA (24 h, 10 µM) and followed by adding 100 µM H2O2. Data are mean ± SD (n = 6).|
|Before Incubation (%)||After Incubation (%)|
|CTRL cells||96.9 ± 2.4||96.0 ± 2.8|
|H2O2 100 µM||61.5 ± 2.8 *|
|H2O2 100 µM + ASTA 10 µM||78.1 ± 1.9 #|
|ASTA 10 µM||97.0 ± 2.2|
* p < 0.01 vs. control cells; # p < 0.01 vs. H2O2 treated cells.
2.2. Cytokines Elisa
Oxidative stress has been shown to promote the production of several cytokines, including pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. U937 cells were treated with either H2O2 or ASTA to investigate the characteristics of pro-inflammatory cytokines production. The single treatment with H2O2 (100 µM) was made for 12 h of culture, whereas the single treatment with ASTA (10 µM) was performed during the 24 h culture. In the combined treatment experiment, U937 cells were treated with 10 µM of ASTA for the first 24 h and then with only 100 µM H2O2 for 12 h. The IL-1β, IL-6 and TNF-α secretion was intensely induced by stimulating the cells with H2O2 compared with the control, but was significantly lower when pre-incubated for 24 h with ASTA before H2O2 stimulation (Figure 1).
2.3. Effect of H2O2 and ASTA on the NF-κB Activity in U937 Cells
Reactive Oxygen Species (ROS) may activate nuclear factors, such as NFkB, leading to the production of pro-inflammatory cytokines, which in turn enhance inflammation and, therefore, the generation of other reactive species . In most cases, NF-κB exists in a heterodimeric form composed of p65 (or RelB) and p50. Furthermore, phosphorylation of the p65 subunit at Ser 536 is associated with activation of NF-κB [23,24]. To identify the NF-κB activation and nuclear translocation after H2O2 stimulation, the phosphorylation levels of p65 subunit were measured by western blot analysis using a phospho-p65-specific Ab anti p-Ser-536 in U937 cells nuclear protein extracts after H2O2 treatment. Also, to test whether the ASTA affect the H2O2 induced activation of NF-κB, U937 cells were pre-treated with ASTA and then stimulated with H2O2 for Western blot analysis using a phospho-p65-specific pAb. Figure 2 showed that nuclear translocation of NF-κB containing the p-p65 subunit was strongly induced H2O2 treatment, but blocked by ASTA pre-treatment. These data suggest NF-κB involvement in ASTA reduction of pro-inflammatory cytokines secretion induced through H2O2 treatment.
2.4. Effect of H2O2 and ASTA on SHP-1 Expression and Phosphatase Activity in U937 Cells
Several reports showed inhibitory effect for SHP-1 phosphatase activity on cytokines secretion . In order to investigate a role for SHP-1 in eliciting ASTA effects in U937 cells, western blot using specific anti-SHP-1 pAb experiments were performed. As shown in Figure 3A treatment with H2O2 strongly down-regulated SHP-1 protein expression. Pre-incubation with ASTA restored SHP-1 basal levels, showing a negative correlation between p65 nuclear translocation and SHP-1 expression. Following this, in order to test whether SHP-1 is involved in the ASTA-mediated inhibition of NF-κB activation, western blot experiments for p-p65 on U937 nuclear extracts protein were performed in the presence of a specific inhibitor of SHP-1 (sodium stibogluconate, SS, 10 µM). Pre-incubation with SS blocked the ASTA-mediated inhibition of NF-κB activity (Figure 3B).
Moreover, pre-incubation with selective SHP-1 inhibitor, blocked ASTA down-regulation of H2O2 induced cytokines release (Table 2). These data indicate that ASTA blocked the H2O2 mediated activation of NF-κB and its downstream cytokines secretion through modulating SHP-1 expression.
|Table 2. IL-1β, IL-6 and TNF-α levels in U937 cells treated with H2O2 (100 µM) + ASTA (10 µM) and pre-incubated or not with sodium stibogluconate (SS, 10 µM). Cytokines released in the culture medium resulted significantly augmented after pre-treatment with SS. Values are expressed as pg/mL. Each value represents the mean ± SD of three independent experiments.|
|IL-1β (pg/mL)||IL-6 (pg/mL)||TNF-α (pg/mL)|
|CTRL cells||34.2 ± 4.9||7.1 ± 2.9||20.4 ± 8.6|
|H2O2 100 µM||90.5 ± 4.5||66.7 ± 6.0||121.4 ± 11.1|
|H2O2 100 µM + ASTA 10 µM||56.9 ± 8.3||41.5 ± 9.4||48.9 ± 12.2|
|H2O2 100 µM + ASTA 10µM + SS 10 µM||88.9 ± 9.5 *||65.2 ± 4.2 *||122.9 ± 12.5 *|
* p < 0.05 vs. H2O2 + ASTA treated cells.
3. Experimental Section
3.1. Cell Culture
U937 mononuclear cells were purchased from American Type Culture Collection (Manassas, VA, USA). The cells were cultured in a 5% CO2 atmosphere in RPMI 1640 medium (GIBCO, Invitrogen) containing 10% fetal calf serum, 100 ng/mL streptomycin, 100 U/mL penicillin and 2 mM L-glutamine. Cells derived from the same freeze-down batch were thawed, grown and seeded (at 2 × 105 cells per well) onto six-well tissue culture plates and cultured in medium with and without 10 µM astaxanthin (ASTA), with and without sodium stigluconate (SS) and treated with H2O2 (100 µM). ASTA was dissolved in dimethyl sulfoxide (DMSO) and diluted with the medium. The final concentration of DMSO in the medium was 0.5%. Control groups not contained ASTA and/or H2O2. Cell viability was determined by trypan blue dye exclusion and MTT assay (Biotium, Hayward, CA, USA).
The primary antibodies used for Western blotting were rabbit anti-SHP-1, anti NF-κB and anti-p-NF-κB (p65) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-β-actin (A5441; Sigma-Aldrich, St. Louis, MO, USA). Astaxanthin was obtained by Sigma-Aldrich. Sodium stibogluconate was purchased from Merck (Darmstadt, Germany).
3.3. Cytokines ELISA
U937 cells were pretreated with ASTA for 24 h. After pre-incubation with ASTA, H2O2 was added to the wells. In other experiment pre-incubation was performed with ASTA and SS. The supernatants were collected and assayed using the Searchligth Elisa kit according to the manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL, USA.).
3.4. Western Blotting
U937 cells were washed once in cold phosphate-buffered saline (PBS; 0.5 mol/L sodium phosphate, pH 7.5) and harvested by gentle scraping, and used to prepare total protein or nuclear extracts. Total protein extracts were prepared by treating cells with lysis buffer [50 mmol/L Tris–HCl pH 7.5, 0.4% Nonidet P-40 (NP-40), 120 mmol/L NaCl, 1.5 mmol/L MgCl2, 2 mmol/L phenylmethylsulphonyl fluoride (PMSF), 1 µg/mL leupeptin, 3 mmol/L NaF and 1 mmol/L dithiothreitol] for 30 min at 4 °C. Nuclear extracts were prepared according to Osborn et al. . Cells were pelleted, frozen in dry ice⁄ethanol, resuspended in 75 µL of Buffer A (10 mmol/L HEPES pH 7.9, 10 mmol/L KCl, 0.5 mmol/L EDTA, 1.5 mmol/L MgCl2, 0.2% NP-40 and 0.5 mmol/L PMSF) and placed on ice for 10 min to allow lysis. Nuclei were pelleted by centrifugation at 3500 g for 10 min at 4 °C, resuspended in 1 mL of Buffer B (20 mmol/L HEPES pH 7.9, 400 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.5 mmol/L EDTA, 25% glycerol and 0.5 mmol/L PMSF) and placed on a rocking platform for 30 min at 4 °C. The nuclear lysates were then clarified by centrifugation at 14,000 g for 20 min at 4 °C and the supernatants (nuclear extracts) collected. The protein concentrations of the extracts were determined using the Bradford method (Bio-Rad protein assay, Hercules, CA, USA). For Western blot analysis, 50 µg of protein per lane was separated on a 4–12% NuPAGE gradient gel (Gibco Invitrogen), electro-transferred on to a nitrocellulose membrane and blocked with 10% skimmed milk in PBS containing 0.1% Tween-20. Blots were probed and incubated overnight at 4 °C with the rabbit polyclonal IgG anti-SHP-1, the rabbit polyclonal IgG anti-pNF-κB and NF-κB (p65) all at 0.2 µg/mL in Tris-buffered saline (TBS)/0.1% Tween-20. A rabbit antihuman monoclonal antibody recognizing the human β-actin was used as control in all experiments. Blots were then washed and incubated for 1 h with goat antirabbit–horseradish peroxidase (Pierce Biotechnology, Rockford, IL, USA) diluted 1:10,000 in TBS/0.1% Tween-20. Immunoblot signals were developed using the Super Signal Ultra chemiluminescence detection reagents (Pierce Biotechnology). The blot images were analyzed with a gel analysis software package (Gel Doc 1000; Bio-Rad, Milan, Italy). Data are expressed as mean ± SD intensity of optical density.
3.5. Statistical Analysis
The results are expressed as mean ± SD. Statistical analysis was performed using analysis of variance (ANOVA). The probability of null hypothesis of <5% (p < 0.05) was considered statistically significant. The comparison H2O2 vs. H2O2 + ASTA and H2O2 + ASTA vs. H2O2 + ASTA + SS was performed using post hoc test with the alpha level at 0.05.
It is well recognized that persistent inflammation contributes to the pathogenesis of many diseases, including cancer, heart disease and atherosclerosis [25,26,27]. The manipulation of the course and intensity of an inflammatory process may occur not only by using agents that inhibit activated “pro-inflammatory pathways”, but also through an approach to activate the natural anti-inflammatory processes, therefore it is essential to identify the metabolic pathways, sensitive to excessive tissue damage, which contribute to the resolution of inflammation. The development of new anti-inflammatory drugs reflects the need to prevent excessive tissue damage that can be established as a result of the persistence of inflammation and at the same time, the need to better understand the processes that contribute to the control and resolution of inflammation. The main properties of astaxanthin inactivate harmful free radicals that are the basis of an inflammatory process. In the immune system, SHP-1 plays critical roles in regulation of many receptor-mediated signaling cascades, and SHP-1 deficiency in mice causes spontaneous inflammation and autoimmunity [28,29]. For the first time our results show that astaxanthin most likely inhibits ROS-induced production of NF-κB transcription factor, which in turn effectively inhibits the production of inflammatory cytokines, through a restoration of physiological levels of SHP-1. Astaxanthin has potential and promising applications in human health because it represents the new frontier of therapy against free radicals . Our future aim will be to demonstrate that the ASTA through the positive regulation of SHP-1 could represent a new therapeutic approach in relation to common inflammatory diseases, even for those affected with allergies cannot benefit from the use of Non-steroidal anti-inflammatory drugs (NSAIDs). In addition, in relation to these findings our goal is to propose the in vitro and in vivo evaluation of ASTA as a positive modulating factor in diseases such as rheumatoid arthritis, where persistent inflammation leads to constant and harmful use of anti-inflammatory molecules (NSAIDs and glucocorticoids).
The Italian Ministry for University and Research is acknowledged for financial support.
- Samples Availability: Available from the authors.
- Bartsch, H.; Nair, J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: Role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 2006, 391, 499–510. [Google Scholar] [CrossRef]
- Libby, P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006, 83, 456S–460S. [Google Scholar]
- Speranza, L.; Franceschelli, S.; Pesce, M.; Reale, M.; Menghini, L.; Vinciguerra, I.; de Lutiis, M.A.; Felaco, M.; Grilli, A. Antiinflammatory effects in THP-1 cells treated with verbascoside. Phytother. Res. 2010, 24, 1398–1404. [Google Scholar]
- Levine, B.; Mizushima, N.; Virgin, H.W. Autophagy in immunity and inflammation. Nature 2011, 469, 323–335. [Google Scholar]
- Riccioni, G.; D’Orazio, N.; Franceschelli, S.; Speranza, L. Marine carotenoids and cardiovascular risk markers. Mar. Drugs 2011, 9, 1166–1175. [Google Scholar]
- Wolf, A.M.; Asoh, S.; Hiranuma, H.; Ohsawa, I.; Lio, K.; Satou, A.; Ishikura, M.; Ohta, S. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J. Nutr. Biochem. 2010, 21, 381–389. [Google Scholar]
- Yuan, J.P.; Peng, J.; Yin, K.; Wang, J.H. Potential health-promoting effects of astaxanthin: A high-value carotenoid mostly from microalgae. Mol. Nutr. Food Res. 2011, 55, 150–165. [Google Scholar]
- Iwamoto, T.; Hosoda, K.; Hirano, R.; Kurata, H.; Matsumoto, A.; Miki, W.; Kamiyama, M.; Itakura, H.; Yamamoto, S.; Kondo, K. Inhibition of low-density lipoprotein oxidation by astaxanthin. J. Atheroscler. Thromb. 2000, 7, 216–222. [Google Scholar]
- Park, J.S.; Chyun, J.H.; Kim, Y.K.; Line, L.L.; Chew, B.P. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr. Metab. (Lond.) 2010, 7. [Google Scholar] [CrossRef]
- Kobayashi, M.; Sakamoto, Y. Singlet oxygen quenching ability of astaxanthin esters from the green alga Haematococcus pluvialis. Biotechnol. Lett. 1999, 21, 265–269. [Google Scholar]
- Yoshida, H.; Yanai, H.; Ito, K.; Tomono, Y.; Koikeda, T.; Tsukahara, H.; Tada, N. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 2010, 209, 520–523. [Google Scholar]
- Lee, S.M.; Kim, E.J.; Suk, K.; Lee, W.H. Synthetic peptides containing ITIM-like sequences of IREM-1 inhibit BAFF-mediated regulation of interleukin-8 expression and phagocytosis through SHP-1 and/or PI3K. Immunology 2011, 134, 224–233. [Google Scholar]
- López-Ruiz, P.; Rodriguez-Ubreva, J.; Cariaga, A.E.; Cortes, M.A.; Colás, B. SHP-1 incell-cycle regulation. Anti-Cancer Agents Med. Chem. 2011, 11, 89–98. [Google Scholar]
- Poole, A.W.; Jones, M.L. A SHPing tale: Perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell. Signal. 2005, 17, 1323–1332. [Google Scholar]
- Scott, L.M.; Lawrence, H.R.; Sebti, S.M.; Lawrence, N.J.; Wu, J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr. Pharm. Des. 2010, 16, 1843–1862. [Google Scholar]
- Yang, J.; Liang, X.; Niu, T.; Meng, W.; Zhao, Z.; Zhou, G.W. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 1998, 273, 28199–28207. [Google Scholar]
- Lawrence, H.R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S.S.; Szymanski, A.M.; Yip, M.L.; Guida, W.C.; Sebti, S.M.; Wu, J.; et al. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem. 2008, 51, 4948–4956. [Google Scholar]
- Christophi, G.P.; Panos, M.; Hudson, C.A.; Tsikkou, C.; Mihai, C.; Mejico, L.J.; Jubelt, B.; Massa, P.T. Interferon-beta treatment in multiple sclerosis attenuates inflammatorygene expression through inducible activity of the phosphatase SHP-1. Clin. Immunol. 2009, 133, 27–44. [Google Scholar]
- Christophi, G.P.; Panos, M.; Hudson, C.A.; Christophi, R.L.; Gruber, R.C.; Mersich, A.T.; Blystone, S.D.; Jubelt, B.; Massa, P.T. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab. Invest. 2009, 89, 742–759. [Google Scholar]
- Christophi, G.P.; Hudson, C.A.; Panos, M.; Gruber, R.C.; Massa, P.T. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 invirus-induced demyelinating disease. J. Virol. 2009, 83, 522–539. [Google Scholar]
- Verhasselt, V.; Goldman, M.; Willems, F. Oxidative stress up-regulates IL-8 and TNF-alpha synthesis by human dendritic cells. Eur. J. Immunol. 1998, 28, 3886–3890. [Google Scholar]
- Josse, C.; Boelaert, J.R.; Best-Belpomme, M.; Piette, J. Importance of post-transcriptional regulation of chemokine genes by oxidative stress. Biochem. J. 2001, 360, 321–333. [Google Scholar]
- Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radical Bio. Med. 2010, 49, 1603–1616. [Google Scholar]
- Osborn, L.; Kunkel, S.; Nabel, G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. USA 1989, 86, 2336–2340. [Google Scholar]
- Zhong, H.; May, M.J.; Jimi, E.; Ghosh, S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol. Cell. 2002, 9, 625–636. [Google Scholar]
- Yang, F.; Tang, E.; Guan, K.; Wang, C.Y. IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by ipopolysaccharide. J. Immunol. 2003, 170, 5630–5635. [Google Scholar]
- Wrigley, B.J.; Lip, G.Y.; Shantsila, E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur. J. Heart Failure 2011, 13, 1161–1171. [Google Scholar]
- Tsui, H.W.; Hasselblatt, K.; Martin, A.; Mok, S.C.; Tsui, F.W. Molecular mechanisms underlying SHP-1 gene expression. Eur. J. Biochem. 2002, 269, 3057–3064. [Google Scholar]
- Anogeianaki, A.; Angelucci, D.; Cianchetti, E.; D’Alessandro, M.; Maccauro, G.; Saggini, A.; Salini, V.; Caraffa, A.; Tete, S.; Conti, F.; et al. Atherosclerosis: A classic inflammatory disease. Int. J. Immunopathol. Pharmacol. 2011, 24, 817–825. [Google Scholar]
- Fassett, R.G.; Coombes, J.S. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009, 5, 333–342. [Google Scholar]
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).